8-K Announcements
6Material company update
May 22, 2026·SEC
Material company update
May 12, 2026·SEC
Material company update
May 4, 2026·SEC
NeuroOne Medical Technologies Corporation(NMTC)Earnings, Financials & Key Ratios
NMTC•NASDAQ
$3.34
Price updated Jun 27, 2026
AboutNeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.Show more
- Revenue$12M+250.4%
- EBITDA-$4M+65.9%
- Net Income-$4M+70.7%
- EPS (Diluted)-0.54+80.4%
- Gross Margin67.3%+115.2%
- EBITDA Margin-32.77%+90.3%
- Operating Margin-34.94%+89.9%
- Net Margin-29.8%+91.6%
- ROE-91.34%+73.8%
NMTC Price & Volume
NeuroOne Medical Technologies Corporation (NMTC) stock price & volume — 10-year historical chart
Loading chart...
Volatile Revenue Growth Masks Persistent Cash Burn
Investment Thesis • Updated 2026Q2
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Capital dilution and liquidity
"NeuroOne Medical Technologies Corporation faces a challenging path to profitability as it struggles to stabilize its lumpy revenue stream, which saw a 72.5% growth spike in 2026Q2 followed by an 11.7% decline in 2026Q1. While the company has successfully improved gross margins to approximately 54%, it remains unable to leverage its $1.9M quarterly SG&A expenses, leading to persistent operating losses. Investors should monitor the company's narrowing cash runway, which dropped from $8.0M in 2025Q3 to $2.8M in 2026Q2, as this trajectory suggests a high probability of future dilutive equity financing."
Verdict Logic
the company's cash reserves have depleted to $2.8M as of 2026Q2, creating significant liquidity risk that likely necessitates further dilutive financing to maintain operations.
NMTC Growth Metrics
NeuroOne Medical Technologies Corporation (NMTC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years163.77%
5 Years44.41%
3 Years313.45%
TTM68.8%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-0.61%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-164.41%
Return on Capital
10 Years-242.78%
5 Years-163.58%
3 Years-157.69%
Last Year-72.62%
NMTC Recent Earnings
NeuroOne Medical Technologies Corporation (NMTC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.25-10.3%
$0.23
Rev
$2M-7.2%
$3M
Q1 2026
Feb 17, 2026Metric
Actual
Est
EPS
$0.18+25.0%
$0.24
Rev
$3M+8.9%
$3M
Q4 2025
Dec 17, 2025Metric
Actual
Est
EPS
$0.05-25.0%
$0.04
Rev
$3M+9.9%
$2M
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.03+40.0%
$0.05
Rev
$2M-6.6%
$2M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.25vs $0.23-10.3% | $2Mvs $3M-7.2% |
| Q1 2026 | Feb 17, 2026 | $0.18vs $0.24+25.0% | $3Mvs $3M+8.9% |
| Q4 2025 | Dec 17, 2025 | $0.05vs $0.04-25.0% | $3Mvs $2M+9.9% |
| Q3 2025 | Aug 14, 2025 | $0.03vs $0.05+40.0% | $2Mvs $2M-6.6% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for NeuroOne Medical Technologies Corporation (NMTC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.34 | $28.79M | -6.19 | 250.35% | -29.8% | -91.34% | — | |
| $83.43 | $4.58B | -18.75 | 10.74% | 7.47% | 9.13% | — | |
| $15.43 | $1.76B | -12.65 | 8.28% | -25.66% | -50.82% | — | |
| $80.98 | $103.97B | 21.71 | 8.43% | 13.2% | 9.78% | — | |
| $93.82 | $163.42B | 25.22 | 5.67% | 13.91% | 12.09% | — | |
| $44.23 | $65.74B | 22.80 | 19.87% | 17.23% | 14.67% | — |
Compare NMTC vs Peers
NeuroOne Medical Technologies Corporation (NMTC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NMTC SEC Filings & Documents
NeuroOne Medical Technologies Corporation (NMTC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when NMTC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NMTC Frequently Asked Questions
NeuroOne Medical Technologies Corporation (NMTC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is NeuroOne Medical Technologies Corporation's revenue?
NeuroOne Medical Technologies Corporation (NMTC) reported $9.7M in revenue for fiscal year 2025. This represents a 832873% increase from $0.0M in 2010.
How fast is NeuroOne Medical Technologies Corporation growing?
NeuroOne Medical Technologies Corporation (NMTC) grew revenue by 250.4% over the past year. This is strong growth.
Is NMTC profitable?
NeuroOne Medical Technologies Corporation (NMTC) reported a net loss of $6.6M for fiscal year 2025.
Dividend & Returns
What is NMTC's return on equity?
NeuroOne Medical Technologies Corporation (NMTC) has a return on equity (ROE) of -91.3%. Negative ROE indicates the company is unprofitable.
What is NeuroOne Medical Technologies Corporation's free cash flow?
NeuroOne Medical Technologies Corporation (NMTC) had negative free cash flow of $7.6M in fiscal year 2025, likely due to heavy capital investments.